A Phase 1 interventional study of Cevostamab and Tocilizumab in Lupus Erythematosus, Systemic, sponsored by Genentech, Inc.. Recruiting at 11 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche — 2 open to participants now, 4 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Hoffmann-La Roche.
Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, this one is the 9th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 1, and was the 14th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →2 of the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche are open now, in 10 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Argentina, Brazil, Colombia and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 5
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 65 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
1 of the studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05835986Hoffmann-La RocheA First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study consists of a dose-escalation stage followed by an expansion stage. Participants in both stages will receive Cevostamab in a step-up dosing regimen, followed by a target dose.
Drug: Cevostamab · Drug: Tocilizumab
Participants will receive cevostamab IV as per the schedule given in the protocol.
Also known as: RO7187797
Tocilizumab may be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
Also known as: Actemra/RoActemra
Percentage of Participants with Adverse Events (AEs)
Time frame: Up to approximately 52 weeks
Serum Concentration of Cevostamab
Time frame: Up to approximately 52 weeks
Area Under the Concentration-Time Curve (AUC) of Cevostamab
Time frame: Up to approximately 52 weeks
Maximum Observed Serum Concentration (Cmax) of Cevostamab
Time frame: Up to approximately 52 weeks
Minimum Observed Serum Concentration (Cmin) of Cevostamab
Time frame: Up to approximately 52 weeks
Clearance (CL) of Cevostamab
Time frame: Up to approximately 52 weeks
Volume of Distribution at Steady State (Vdss) of Cevostamab
Time frame: Up to approximately 52 weeks
Change from Baseline in the Presence Anti-Drug Antibodies (ADAs)
Time frame: Up to approximately 52 weeks
Plan to share: No
Started Nov 2026 (actual). Primary completion is estimated for Mar 2030, 40 months after the start.
Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 40 months is above that.
Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cevostamab
Lupus Erythematosus, Systemic →